First trial of the HIV-1 vaccine in Africa: Ugandan experience
BMJ 2002; 324 doi: https://doi.org/10.1136/bmj.324.7331.226 (Published 26 January 2002) Cite this as: BMJ 2002;324:226Data supplement
- Other members of the HIV-1 Vaccine Trial Group are:
Family Health International, P O Box 13950, Research Triangle Park, NC 27709, USA
Kathleen George
epidemiologistMelissa Allen
epidemiologistJoint Clinical Research Center, P O Box 10005, Kampala, Uganda
Anthony Kebba
doctorCissy Kityo
research coordinatorCase Western Reserve University, School of Medicine, Tuberculosis Research Unit, Cleveland, OH 44106-4984 USA
John L Johnson
associate professorSchelleingassee 6/16, A-1040 Vienna, Austria
Claudia Schmidt
doctorUganda Virus Research Institute, P O Box 49, Entebbe, Uganda
Sylvester D Sempala
directorInternational AIDS Vaccine Initiative (IAVI), Uganda Virus Research Institute, P O Box 22616, Kampala, Uganda
Emmanuel Mugisha
social scientistClinical Development Branch, Division of AIDS/Clinical Development Branch, National Institute of Allergy and Infectious Diseases, Bethesda, MD 20892, USA
Jorge Flores
research scientistViral and Rickettsial Disease Laboratory, Division of Communicable Disease Control, California Department of Health Services, Richmond, CA 94804-6403, USA
C Haynes Sheppard
research scientist IIIHuyen Cao
doctorHIVNET 007 protocol team
Additional members participated in this study: John Bosco-Mukasa, Joint Clinical Research Centre, Kampala, Uganda; Benon Biryahwaho, Uganda Virus Research Institute, Entebbe, Uganda; Raphaelle El Habib, Aventis-Pasteur, Marnes la Coquette, France; Jean-Louis Excler, US Military HIV Research Program, Rockville, MD, USA; Patricia Fast, International AIDS Vaccine Initiative, New York, NY, USA; Thomas Fleming, University of Washington, Seattle, WA, USA; Mark Grabowsky, American Red Cross, Washington, DC, USA; Rodney Hoff, National Institute of Allergy and Infectious Diseases and National Institutes of Health, Bethesda, MD, USA; Dale Lawrence, National Institute of Allergy and Infectious Diseases and National Institutes of Health, Bethesda, MD, USA; Anita Loughlin, Johns Hopkins University, Baltimore, MD, USA; Leslie Nielsen, International AIDS Vaccine Initiative, Entebbe, Uganda; Grace Svilar, Case Western Reserve University, Cleveland, OH, USA; Bruce Walker, Massachusetts General Hospital, Charleston, MA, USA; Courtney Walker, Case Western Reserve University, Cleveland, OH, USA; and Kent Weinhold, Duke University, Durham, NC, USA.
Related articles
- Editor's Choice Published: 26 January 2002; BMJ 324 doi:10.1136/bmj.324.7331.0i
- Clinical Review Published: 26 January 2002; BMJ 324 doi:10.1136/bmj.324.7331.211
See more
- The future of NHS dentistry in ScotlandBMJ December 05, 2016, 355 i6466; DOI: https://doi.org/10.1136/bmj.i6466
- Seven days in medicine: 23-29 November 2016BMJ December 01, 2016, 355 i6433; DOI: https://doi.org/10.1136/bmj.i6433
- Oral cancer rates rise by two thirdsBMJ November 25, 2016, 355 i6369; DOI: https://doi.org/10.1136/bmj.i6369
- Dentistry: should it be in the NHS at all?BMJ November 10, 2016, 355 i5986; DOI: https://doi.org/10.1136/bmj.i5986
- Lamb ingestion and odynophagiaBMJ November 02, 2016, 355 i5506; DOI: https://doi.org/10.1136/bmj.i5506